Luteinizing Hormone Involvement in Aging Female Cognition: Not All Is Estrogen Loss

Sabina Bhatta¹, Jeffrey A. Blair¹ and Gemma Casadesus¹,²*

¹ School of Biomedical Sciences, Kent State University, Kent, OH, United States, ² Department of Biological Sciences, Kent State University, Kent, OH, United States

Pervasive age-related dysfunction in hypothalamic-pituitary-gonadal (HPG) axis is associated with cognitive impairments in aging as well as pathogenesis of age-related neurodegenerative diseases such as the Alzheimer's disease (AD). As a major regulator of the HPG axis, the steroid hormone estrogen has been widely studied for its role in regulation of memory. Although estrogen modulates both cognition as well as cognition associated morphological components in a healthy state, the benefits of estrogen replacement therapy on cognition and disease seem to diminish with advancing age. Emerging data suggests an important role for luteinizing hormone (LH) in CNS function, which is another component of the HPG axis that becomes dysregulated during aging, particularly in menopause. The goal of this review is to highlight the current existing literature on LH and provide new insights on possible mechanisms of its action.

Keywords: luteinizing hormone, luteinizing hormone receptor, cognition, menopause, estrogen, ovariectomy, inverse relationship

INTRODUCTION

Our ability to successfully treat midlife diseases has increased human longevity as well as the prevalence of age-associated neurodegenerative diseases such as the Alzheimer’s disease (AD). While a small percentage of AD is precipitated by dominant mutations, the majority is sporadic and is highly associated with environmental/lifestyle choices as well as the physiological aging process. In fact, aging is the strongest risk factor for development for AD, the most common form of dementia (1–3). As baby boomers age, millions of people are at risk for AD and other cognitive diseases. This is especially relevant as the number of AD diagnosis is expected to rise from current 5.7 million to 14 million by 2050, and the cost of disease is projected to rise to 1.1 trillion dollars creating a broad economic and social impact. Therefore, identifying therapeutic targets to delay, modify, or cure the disease is of paramount importance.

Menopause, a hallmark of aging in women, is associated with dysfunctions in the hypothalamic-pituitary-gonadal (HPG) axis and is implicated in the pathogenesis of AD. Age-related declines in reproductive hormones lead to a disarray of the HPG axis as it is tightly regulated by positive and negative feedback loops involving gonadotropin releasing hormone (GnRH), gonadal steroids, and gonadotropins. The loss of any component leads to significant dysregulation of the system and any type of hormonal imbalance likely affects homeostasis resulting in functional decline throughout...
the body, including the brain (4–8). In fact, these declines in gonadal hormones, and associated increases in gonadotropins such as LH are implicated in cognitive dysfunction in aging as well as the pathogenesis of age-related disorders such as AD. This is particularly relevant for women as they have two-fold higher risk for development of AD after menopause compared to men.

HORMONE REPLACEMENT THERAPY (HRT) FOR COGNITION AND AD

Several studies attribute increased risk of AD to the menopausal loss of estrogen (9, 10) and considered estrogen replacement a promising therapeutic avenue to reduce the risk of AD (11–14). This was initially supported by early epidemiological studies identifying strong relationships between estrogen therapy in post-menopausal women and reductions in multiple types of memory decline, specifically, in menopausal women with and without AD (15, 16).

Clinically, estrogen replacement or HRT showed initial promise in smaller clinical retrospective (17–20) and prospective studies (21–23). However, a large scale, randomized, double-blind placebo-controlled trial, women’s health initiative WHI found no overall cognitive benefits. While the use of estrogen immediately or after a smaller delay following onset of menopause was effective, HRT in women at least 15 years after onset of menopause slightly increased the risk of dementia instead (24–26). This discrepancy in actions of estrogen on memory and dementia risk lead several groups to hypothesize that a “critical period” may exist following onset of menopause where estrogen can confer benefits, beyond which it is ineffective and may instead exert harmful effects (27–31). These clinical observations were further supported by pre-clinical work in ovariectomized rodents (32) and primates (33) providing support for the existence of a critical window for the initiation of estrogen for optimal enhancement of cognitive function (34).

One mechanism purported to underlie the ineffectiveness of estrogen treatment beyond a critical period is the “healthy cell bias” wherein estrogen is beneficial to healthy cells, but detrimental to unhealthy ones (35, 36). This was further supported by the fact that critical plasticity and cognition related proteins such as BDNF (37) and the cholinergic system (38) differ in young and old rats. Based on the above theory, more recent clinical randomized trials addressed the potential benefit of estrogen therapy considering timing of replacement. Unfortunately, these studies have yielded little support for this hypothesis (39–42). Together, these data suggest that while estrogen is relevant and important for CNS function and structure during the reproductive periods, aspects beyond estrogen loss contribute to age-related menopausal dysfunction.

INvolvement of Luteinizing Hormone (LH) in CNS Function and AD

Accumulating evidence supports a role for LH in regulating cognition and AD-related parameters. LH, a gonadotropin hormone released from the anterior pituitary, functions to stimulate the production of sex steroids, which in turn negatively regulate hypothalamic GnRH release and further production of LH. In the absence of sex steroids providing negative feedback, LH levels drastically increase, as observed following menopause and andropause. Peripheral levels of LH increase three-fold in post-menopausal women (43) and two-fold in aging men (44). Importantly, these increases in peripheral LH levels correlate to cognitive deficits in aging men and women (45, 46) as well as AD patients (47–51). In fact, increased levels of peripheral LH in AD patients is associated with exacerbated pathology and cognitive deficits (50–52). Additionally, increased LH is correlated with increased plasma Aβ1−40 and Aβ1−42 levels in subjective memory complainers, suggesting LH may play a progressive role in early preclinical stages (51).

In rodents, earlier studies demonstrated that over-expression of LH in transgenic mice (53), or exogenous treatment with human LH (54) without any estrogen manipulations, impaired working memory. These studies are supported by work showing that chronic elevations in peripheral levels through exogenous application of the LH analog, human chorionic gonadotropin (hCG), results in similar attenuation of working memory as well as increases in total brain amyloid-β1−40 in a mouse model of AD (55, 56). Moreover, peripheral increase in hCG is capable of reversing estrogen associated benefits in spatial memory (55, 56).

Several studies involving pharmacological downregulation of peripheral LH after ovariectomy also support a role for LH in cognition and plasticity. To this end, work utilizing either GnRH super-agonist (57–60) or competitive antagonists (61–64) of the GnRH receptor reverse cognitive deficits (57–64) and neuronal plasticity loss (59, 60) in the absence of estrogen replacement. For example, several studies from our lab using GnRH super-agonist, leuprolide acetate, improved function in ovariectomized C57BL/6J mice (58, 60) as well as aged-ovariectomized 3xTg AD mice (59). Furthermore, these benefits were associated with activation of signaling cascades associated with long term potentiation (LTP), the cellular basis of learning and memory, Bryan et al. (58) in the absence of AD pathology (59), further supporting a direct role of LH-related mechanisms on cognition. More importantly, a key finding was that pharmacological reductions in peripheral levels of LH lead to cognitive improvements and rescue of dendritic spine density without any dependence on timing of treatment onset (60). This raises the exciting possibility that LH may provide an additional therapeutic target for rescuing cognitive and structural deficiencies associated with menopause, aging, and AD.

While there is no clinical data to support the benefits of peripheral downregulation of LH in menopausal women, clinical data in AD patients support its validity (65). A small, phase II, randomized, clinical trial, in female patients with moderate AD, showed that leuprolide acetate stabilized cognitive function in a subgroup treated with an acetylcholinesterase inhibitor, Aricept. Given Aricept is the primary treatment option for AD patients, these data are encouraging. However, while clinical and preclinical studies show promise for LH-related therapeutics, the...
mechanisms underlying these effects remain unknown to date. In the next sections, we highlight a potential mechanism of action of these therapies in relation to signaling and function of the LH receptor.

**LH SIGNALING AND COGNITION**

LH as well its receptor LHR are expressed in the CNS (66–69). Importantly, LHR is present in regions associated with learning and memory (68–70). Similarly, LHR is also expressed in the choroid plexus, ependymal cells of the third, fourth and lateral ventricles as well as the area postrema (68), which are areas involved in production and circulation of cerebrospinal fluid CSF as well as blood brain barrier transport, suggesting a potential modulatory role of LHR in BBB permeability.

The LHR is a G-protein-coupled receptor involved in production of sex steroids in the gonads through Gs cAMP/PKA, ERK and Gq PLC pathways. Gq signaling results in phosphorylation of MAPK and CREB, while Gs induces intracellular Ca2+ release and activation of several protein kinases such as PKA and CAMKII (71–74). LHR activated cAMP/PKA signaling cascades in the immortalized cultures of hippocampal and hypothalamic neurons in vitro (75, 76). Interestingly, these signaling cascades downstream of LHR are associated with gene expression and structural changes that are the hallmark of synaptic plasticity and memory formation in the CNS (77–80) and induction of LTP (81–84). Furthermore, active kinases trigger activation of transcriptional factors such as MAPK and CREB leading to gene expression and structural remodeling of the synapse. This ultimately leads to enhanced synaptic transmission and BDNF production, as well as plasticity of dendritic spines (79, 85–87). However, as previously discussed above, downregulation of peripheral LH in the ovX model lead to CAMKII autophosphorylation at Thr 286 and CAMKII dependent GluR1 Ser 831 phosphorylation (58), inhibition of GSK3β and upregulation of β-catenin in 3X Tg mouse model of AD (59), and improved cognitive function. Based on the known canonical signaling cascades ascribed to the LHR, these data, at least indirectly, suggest activation rather than inhibition of the LHR, thus, in conflict with the prevalent idea that LH signaling in the CNS is detrimental.

The idea that LH signaling in the CNS is detrimental stems from the supposition that LH crosses the blood-brain-barrier (BBB); however, LH is a large glycoprotein that is unlikely to penetrate the BBB without a transporter molecule. Furthermore, both human and animal studies show contradictory evidence on whether hCG or LH can cross the BBB. One study showed some permeability of hCG into CNS when administered at supra-physiological levels (88) while another did not (89). Moreover, studies show hCG is not BBB permeable in human choriocarcinomas models until a high threshold is reached (90, 91), especially in patients with normal levels of plasma LH (92). These data suggest that hCG and LH may not be permeable in normal or OVX conditions, thus, the supposition that the LHR is detrimental is difficult to reconcile.

**BRAIN-SPECIFIC LH AS MECHANISM FOR LHR-MEDIATED CNS FUNCTION**

Several earlier studies have demonstrated the expression of LH in the brain of various species (59, 66, 67), as well as its ability to modulate synaptic function (93–95), neurogenesis (96), and behavior (59, 88, 97, 98). In vitro, administration of the LH analog hCG, which binds and activates the LHR similarly to LH (99, 100), stimulates neurite outgrowth in rat neuronal culture and differentiation in PC12 cells through activation of the erk/MAPK pathway (99, 101). Erk/MAPK is a pathway that is critical for memory function and plasticity (78). Similarly, LHR activation in vitro also leads to stem cell differentiation (102), and protection against excitotoxicity in primary neurons (103).

LHR transcripts as well as functional receptors have been found in neurons and glial cells in vitro (94, 95). LHR was functional in vitro in neurons cultured at embryonic day 19. Similarly, hCG treatment of mixed glial cultures, from either P0 or P1 neonates, for 3 days lead to a dose-dependent increase in anti-inflammatory prostaglandin (PG), PGD2 and decrease in proinflammatory PGE2. These actions of LHR may be important for neonatal brain development and function as PGE2 inhibits the proliferation of glial cells, while PGD2 may do the exact opposite. Therefore, LHR signaling may be promoting controlled proliferation of glial cells during brain development (94).

While the above cited works cannot conclusively identify the source of LH in the brain, these studies demonstrate the presence of LH in cognition associated areas and its ability to mediate signaling and behavior. Furthermore, the highlighted in vitro work validates CNS LHR functionality and signaling consistent with cognition and neuroplasticity, both through neurons and glial cells. This said, how the LHR is involved in menopause and ovariectomy-induced cognitive and neuroplasticity loss remains unclear but may be explained through alterations in brain and peripheral levels of LH, as highlighted in the section below.

**INVERSE RELATIONSHIP BETWEEN PERIPHERY AND THE BRAIN**

Accumulating research shows that LH levels in the brain may have an inverse relationship to the periphery. For example, in studies of cycling adult female rats, hypothalamic LH decreased during proestrus, when a drastic 10-fold increase in LH occurs in the pituitary and periphery (104). Similarly, LH treatment into the median eminence (ME) of the hypothalasus in intact or castrated males and females significantly decreased both LH levels in the pituitary as well as the periphery (105). In a similar experiment, hCG treatment into the median eminence of hypothalasus in ovariectomized as well as intact mature female rats decreased peripheral LH (106).
Additionally, LH mRNA levels are reduced in both the hippocampus and the cortex of human female AD brains (59), although they are increased in the periphery (47, 48). Interestingly, LH immunoreactivity is remarkably reversed when peripheral LH levels are downregulated and lead to improved cognition (59). These experiments, therefore, provide ample support to the idea of inverse relationship between peripheral LH and central LH, and further suggest that the LH and hCG in the periphery are capable of self-regulating their levels through short-loop feedback into the brain (105, 107, 108).

Interestingly, ovariectomized rats have no changes in hypothalamic LH, although the pituitary and serum LH levels are elevated eight-fold (104). Furthermore, the self-regulated decrease in peripheral LH in response to IV treatment of hCG and hLH seen in rabbits 2 weeks following castrations was absent 6 weeks following castrations, suggesting the sensitivity of the short-loop changes with time after castration (107). This begs the question of whether self-regulation of hypothalamic LH production is more pertinent than gonadal loss, and importantly, whether loss of this “short” feedback in menopause underlies the “critical period” sensitivity observed for estrogen. The fact that the LHR is rapidly internalized in the presence of its ligands (109–113) may provide a potential explanation for the loss of short-feedback loop, as impairments in LHR signaling due to ligand-induced internalization may reduce the ability to signal back to the hypothalamus. This may also explain the work postulating that activation of LHR is deleterious to cognition (52, 62, 88, 114) as the above studies used supraphysiological doses of exogenous hCG. In one of the studies above, deglycosylated hCG used as the LHR antagonist improved cognition; however, validation of the levels of LHR or verification of full deglycosylation of hCG was not performed (114). Therefore, further studies need to be carried out with careful consideration of LH dose and LHR internalization to clarify the role of LHR in the CNS.

An additional aspect that has confounded our ability to clearly dissect the function of the LHR in the CNS from that of loss of gonadal steroids is the fact that LHR has not been modulated in a brain-specific manner. For example, one article demonstrated that knocking out LHR in an AD mouse model attenuated the pathology and cognitive deficits (115). However, the LHR knockout model was global, not brain-specific, thus early developmental effects due to deficits in sex steroids, which are known in these animals, cannot be separated from the role of LHR loss.

**CONCLUSIONS**

Among a multitude of changes that occur with aging, menopause is a clear driver for development of AD in women. The role of steroid hormones in CNS function and structure, particularly during reproductive stages, is undisputed and here we provide evidence that LH and its receptor are important in CNS function as well as dysfunction as depicted in the working model of LH action in Figure 1. We also highlight a potential mechanism, specifically the inverse relationship of LH levels in the CNS vs. the periphery, to provide an explanation for the paradox observed between the ability of the LHR to activate cascades associated...
with learning, memory and neuroplasticity, and the findings demonstrating benefits of peripheral LH downregulation on these aspects. Further investigation is necessary to understand how the inverse relationship of LH between the periphery and the CNS is maintained as well as to identify the molecular mechanisms underlying LH-related memory and plasticity benefits in a CNS-specific manner. Genetic approaches targeting the LHR specifically within the brain are likely to be useful models to conclusively address the role of the LHR in CNS function and structure.

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

FUNDING

Our works cited in this manuscript have been funded by the NIH grant, RF1 AG054654-01.

REFERENCES

1. Alzheimer’s Association. 2018 Alzheimer’s disease facts and figures. Alzheimer’s Dement. (2018) 14:367–429. doi: 10.1016/j.jalz.2018.02.001
2. Castellani RJ, Rolston RK, Smith M. Alzheimer disease. Dis Mon. (2011) 56:1–60. doi: 10.1016/j.diabmon.2010.06.001.Altzheimer
3. Maki PM, Henderson VW. Hormone therapy, dementia, and cognition: the Women’s Health Initiative 10 years on. Climacteric (2012) 15:256–62. doi: 10.3109/13697317.2012.660613
4. McEwen BS, Alves SE, Bulloch K, Weiland NG. Clinically relevant basic science studies of gender differences and sex hormone effects. Psychopharmacol Bull. (1998) 34:251–9.
5. McEwen BS, Alves SE. Estrogen actions in the central nervous system. Endocr Rev. (1999) 20:279–307. doi: 10.1210/edrv.20.3.0365
6. Hojo Y, Hattori T-A, Enami T, Furukawa A, Suzuki K, Ishii H-T, et al. Adult male rat hippocampus synthesizes estradiol from pregnenolone by cytochromes P45017alpha and P450 aromatase localized in neurons. Proc Natl Acad Sci USA. (2004) 101:865–70. doi: 10.1073/pnas.2630225100
7. Gibbs RB. Estrogen therapy and cognition: a review of the cholinergic hypothesis. Endocr Rev. (2010) 31:224–53. doi: 10.1210/edrv.2009-0036
8. Bowen RL, Atwood CS. Living and dying for sex: a theory of aging. Proc Natl Acad Sci USA. (1994) 91:5722–7. doi: 10.1073/pnas.91.12.5722
9. Zandi PP, Carlson MC, Plassman BL, Welsh-Bohmer KA, Mayer LS, Steffens DC, et al. Rates and risk factors for dementia and Alzheimer’s disease. Neurology (1999) 53:78–LP–78.
10. Andersen K, Launer LJ, Dewey ME, Letenneur L, Ott A, Copeland JRM, et al. Gender differences in the incidence of AD and vascular dementia. Neurology (1999) 53:1992LP–1992.
11. Zandi PP, Carlson MC, Plassman BL, Welsh-Bohmer KA, Mayer LS, Steffens DC, et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. J Am Med Assoc. (2002) 288:2123–9. doi: 10.1001/jama.288.21.2123
12. Kawas C, Resnick S, Morrison A, Brookmeyer R, Corrada M, Zonderman A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer’s disease: the Baltimore Longitudinal Study of Aging. Neurology (1997) 48:1517–21.
13. Hogervorst E, Williams J, Budge M, Riedel W, Jolles J. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis. Neuroscience (2000) 101:485–512. doi: 10.1016/S0306-4522(00)00410-3
14. Yang MX, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer’s disease. Lancet (1996) 348:429–32.
15. Hogervorst E, Yaffe K, Richards M, Huppert F. Hormone replacement therapy to maintain cognitive function in women with dementia. Cochrane Database Syst. Rev. (2009) 1:CD003799. doi: 10.1002/14651858.CD003799.pub2
16. Rocca WA, Grossardt BR, Shuster LT. Oophorectomy, estrogen, and dementia: a 2014 update. Mol Cell Endocrinol. (2014) 389:7–12. doi: 10.1016/j.mce.2014.01.020.Oophorectomy
17. Henderson VW, Paganini-Hill A, Emanuel CK, Dunn ME, Buckwalter JG. Estrogen replacement therapy in older women. Comparisons between Alzheimer’s disease cases and nondemented control subjects. Arch Neurol. (1994) 51:896–900.
18. Kampen DL, Sherwin BB. Estrogen and verbal memory in healthy postmenopausal women. Obstet Gynecol. (1994) 83:979–83.
19. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. J Am Med Assoc. (1998) 279:688–95.
20. Yaffe K, Haan M, Byers A, Tangen C, Kuller L. Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction. Neurology (2000) 54:1949 LP–1954. doi: 10.1212/WNL.54.10.1949
21. Sherwin BB. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology (1998) 13:345–57. doi: 10.1016/S0306-4530(98)00601-9
22. Sherwin BB. Can estrogen keep you smart? Evidence from clinical studies. J Psychiatry Neurosci. (1999) 24:315–21.
23. Phillips SM, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology (1992) 17:485–95.
24. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the women’s health initiative memory study: a randomized controlled trial. JAMA (2003) 289:2651–62. doi: 10.1001/jama.289.20.2651
25. Shumaker SA, Legault C, Rapp SR, Thal L, Lane DS, Follit H, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women Women’s Health Initiative Memory Study. JAMA (2004) 291:2947–58. doi: 10.1001/jama.291.24.2947
26. Espeland MA, Rapp SR, Shumaker SA, Brunner R, Manson JE, Sherwin BB, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women Women’s Health Initiative Memory Study. JAMA (2004) 291:2959–68. doi: 10.1001/jama.291.24.2959
27. Resnick SM, Henderson VW. Hormone therapy and risk of Alzheimer disease: a critical time. J Am Med Assoc. (2002) 288:2170–2. doi: 10.1001/jama.288.17.2170
28. Henderson VW. Hormone therapy and Alzheimer’s disease: benefit or harm? Expert Opin Pharmacother. (2004) 5:389–406. doi: 10.1517/14656565.5.2.389
29. Sherwin BB. Estrogen and cognitive functioning in women: lessons we have learned. Behav Neurosci. (2012) 126:123–7. doi: 10.1037/a0025539
30. Shao H, Breitner JCS, Whitmer RA, Wang J, Hayden K, Wengreen H, et al. Hormone therapy and Alzheimer disease dementia: new findings from the cache county study. Neurology (2012) 79:1846–52. doi: 10.1212/WNL.0b013e3182718223
31. Singh M, Simpkins JW, Binomote-Nelson HA, Brinton RD. Window of opportunity for estrogen and progesterin intervention in brain aging and Alzheimer’s disease. Brain Res. (2013) 1514:1–2. doi: 10.1016/j.brainres.2013.04.044
32. Gibbs R. Long-term treatment with estrogen and progesterone enhances acquisition of a spatialmemory task by ovariectomized aged rats. Neurobiol Aging (2000) 21:107–16. doi: 10.1016/S0197-4580(00)00103-2
33. Lacreuse A, Wilson ME, Herndon JG. Estradiol, but not raloxifene, improves aspects of spatial working memory in aged ovariectomized rhesus monkeys. Neurobiol Aging (2002) 23:589–600. doi: 10.1016/S0197-4580(02)00002-7
Bhatta et al. Role of LH in the Aging Female Cognition

34. Gibbs RB, Gabor R. Estrogen and cognition: applying preclinical findings to clinical perspectives. *J Neurosci Res.* (2003) 74:637–43. doi: 10.1002/jnr.10811

35. Zhao L, Chen S, Ming Wang J, Brinton RD. 17β-estradiol induces Ca2+ influx, dendraitic and nuclear Ca2+ rise and subsequent cyclic AMP response element-binding protein activation in hippocampal neurons: a potential initiation mechanism for estrogen neurotoxicity. *Neuroscience* (2005) 132, 299–311. doi: 10.1016/j.neuroscience.2004.11.054

36. Brinton RD. The healthy cell bias of estrogen action: mitochondrial bioenergetics and neurological implications. *Trends Neurosci.* (2008) 31:529–37. doi: 10.1016/j.tins.2008.07.003

37. Jeziorski MK, Sohrabi F. Neurotrophin expression in the reproductive senescent forebrain is refractory to estrogen stimulation. *Neurol Biol Aging* (2001) 22:311–21. doi: 10.1016/S0197-4580(00)00230-X

38. Markowska AL, Savonenko AV. Effectiveness of estrogen replacement in restoration of cognitive function after long-term estrogen withdrawal in aging rats. *J. Neurosci.* (2002) 22:10985–95. doi: 10.1523/JNEUROSCI.22-24-10985.2002

39. Espeland MA, Shumaker SA, Leng I, Manson JE, Brown CM, LeBlanc ES, et al. Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years. *JAMA Intern Med.* (2013) 173:1429–36. doi: 10.1001/jamainternmed.2013.7727

40. Gleason CE, Dowling NM, Wharton W, Manson JAE, Miller VM, Atwood CS, et al. Effects of hormone therapy on cognition and mood in recently postmenopausal women: findings from the randomized, controlled KEEPS–cognitive and affective study. *PloS Med.* (2015) 12:e128. doi: 10.1371/journal.pmed.1001833

41. Henderson VW, St John JA, Hodis HN, McCleary CA, Stanczyk FZ, Shoupe D, et al. Cognitive effects of estradiol after menopause. *Neurology* (2016) 87:699–708. doi: 10.1212/WNL.0000000000029890

42. Imitz B, Tuppuranen M, Rikkonen T, Tanaka M, Schally AV. Effects of the LHRH antagonist on plasma amyloid-beta protein levels in elderly men. *Exp. Gerontol.* (2004) 39:1633–9. doi: 10.1016/j.exger.2004.06.019

43. Nicas JD, Palm R, Chang J, Blair J, Cars, personal communication. (2013) 39:1633–9. doi: 10.1016/j.exger.2004.06.019

44. Neaves WB, Johnson L, Porter JC, Parker CRJ, Petty CS. Leydig cell numbers, daily sperm production, and serum gonadotropin levels in aging men. *J. Clin Endocrinol Metab.* (1989) 69:756–63. doi: 10.1210/jcem-69-4-756

45. Hyde Z, Flicker L, Almeida OP, McCaul KA, Jamrozik K, Hankey GJ, et al. Human chorionic gonadotropin: a potential clinical perspective. *J. Neurosci.* (2009) 29:870–81. doi: 10.1523/JNEUROSCI.22-24-10985.2002

46. Hughes J, Langa K, Phillips C, Plassman B, Williams C, Katz M, et al. Cognition and physical function in hospitalized oldest old patients. *Exp. Gerontol.* (2014) 130:115–25. doi: 10.1111/jnc.12706

47. Brinton RD, Barron AM, Whadee K, Biddle B, Martinis R, et al. Direct exposure of guinea pig CNS to human luteinizing hormone increases cerebrospinal fluid and cerebral beta amyloid levels. *Neuroendocrinology* (2011) 94:313–22. doi: 10.1016/j.yhbeh.2008.02.006

48. Bryan KJ, Mudd JC, Richardson SL, Chang J, Lee HG, Zhu X, et al. Down-regulation of serum gonadotropins is as effective as estrogen replacement at improving menopause-associated cognitive deficits. *J. Neurochem.* (2010) 112:870–81. doi: 10.1111/j.1471-4159.2009.06502.x

49. Palm R, Chang J, Blair J, Garcia-Mesa Y, Lee H, Castellani RJ, et al. Down-regulation of serum gonadotropins but not estrogen replacement improves cognition in aged-ovariectomized 3xTg AD female mice. *J. Neurochem.* (2014) 130:115–25. doi: 10.1111/jnc.12706

50. Blair JA, Palm R, Chang J, McGee H, Zhu X, Wang X, et al. Luteinizing hormone modulates cognition and amyloid-beta deposition in Alzheimer APP transgenic mice. *Biochim Biophys Acta* (2006) 1762:447–52. doi: 10.1016/j.bbads.2006.01.008

51. Telegdy G, Tanaka M, Schally AV. Effects of the LHRH antagonist on plasma amyloid-beta protein levels in elderly men. *Exp. Gerontol.* (2004) 39:1633–9. doi: 10.1016/j.exger.2004.06.019

52. Nicas JD, Palm R, Chang J, Blair J, Cars, personal communication. (2013) 39:1633–9. doi: 10.1016/j.exger.2004.06.019

53. Casadesus G, Milliken EL, Webber KM, Bowen RL, Lei Z, Rao CV, et al. Increases in luteinizing hormone are associated with declines in cognitive performance. *Mol Cell Endocrinol.* (2007) 269:107–11. doi: 10.1016/j.mce.2006.06.013

54. Casadesus G, Milliken EL, Webber KM, Bowen RL, Lei Z, Rao CV, et al. Increases in luteinizing hormone are associated with declines in cognitive performance. *Mol Cell Endocrinol.* (2007) 269:107–11. doi: 10.1016/j.mce.2006.06.013
hormone receptor gene in transgenic mice. Endocrinology (1999) 140:5322–9.

71. Ascoli M, Fanelli F, Segaloff DL. The lutropin/choriogonadotropin receptor, A 2002 perspective. Endocr Rev. (2002) 23:141–74. doi: 10.1210/edrv-23-2.09462

72. Herzlich A, Kühn B, Grosse R, Schmid A, Schultz G, Gudermann T. Involvement of Gs and Gi proteins in dual coupling of the luteinizing hormone receptor to adenylyl cyclase and phospholipase C. J Biol Chem. (1996) 271:16764–72.

73. Gudermann T, Nichols C, Levy FO, Birnbaumer M, Birnbaumer L. Ca2+ mobilization by the LH receptor expressed in Xenopus oocytes independent of 3,5′-cyclic adenosine monophosphate formation: evidence for parallel activation of two signaling pathways. Mol Endocrinol. (1992) 6:272–8.

74. Gudermann T, Birnbaumer M, Birnbaumer L. Evidence for dual coupling of the murine luteinizing hormone receptor to adenylyl cyclase and phosphoinositol breakdown and Ca2+ mobilization. J Biol Chem. (1992) 267:4479–88.

75. Lei ZM, Rao CV. Novel presence of luteinizing hormone/human chorionic gonadotropin (hCG) receptors and the down-regulating action of hCG on gonadotropin-releasing hormone gene expression in immortalized hypothalamic GT1-1 neurons. Mol Endocrinol. (1994) 8:1111–21. doi: 10.1210/mend.8.8.7997235

76. Zhang W, Lei ZM, Rao CV. Immortalized hippocampal cells contain functional luteinizing hormone/human chorionic gonadotropin receptors. Life Sci. (1999) 65:2083–98. doi: 10.1016/S0024-3205(99)00474-9

77. Atkins CM, Selcher JC, Petraitis JJ, Trzaskos JM, Sweatt JD. The MAPK cascade is required for mammalian associative learning. Nat Neurosci. (1998) 1:602–9.

78. English JD, Sweatt JD. A requirement for the mitogen-activated protein kinase cascade in hippocampal long term potentiation. J Biol Chem. (1997) 272:19103–6.

79. Matsuzaki M, Honkura N, Ellis-Davies GC, Kasai H. Structural basis of long-term potentiation in single dendritic spines. Nature (2004) 429:761–6. doi: 10.1038/nature02617

80. Kasai H, Matsuzaki M, Noguchi J, Yasumatsu N, Nakahara H. Structure-stability-function relationships of dendritic spines. Trends Neurosci. (2003) 26:360–8. doi: 10.1016/S0166-2236(03)00162-0

81. Roche KW, O’Brien RJ, Mammel AL, Bernhardt J, Huganir RL. Characterization of multiple phosphorylation sites on the AMPA receptor GluR1 subunit. Neuron (1996) 16:1179–88.

82. Barria A, Muller D, Derkach V, Griffith LC, Soderling TR. Regulatory phosphorylation of the alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor GluR1 subunit by calcium/calmodulin-dependent kinase II. J Biol Chem. (1997) 272:32528–33.

83. Lee HK, Barbaroie M, Kameyama K, Bear MF, Huganir RL. Regulation of distinct AMPA receptor phosphorylation sites during bidirectional synaptic plasticity. Nature (2000) 405:955–9. doi: 10.1038/35016089

84. Nusser Z, Lujan R, Mammen AL, Kameyama K, Roche KW, Huganir RL. Phosphorylation of the lutropin/choriogonadotropin receptor: an unusual member of the G protein-coupled receptor family. Science (2007) 318:494–9. doi: 10.1126/science.1148642

85. Hirono M, Igarashi M, Matsumoto S. The direct effect of hCG on gonadotropin releasing hormone gene expression in immortalized hypothalamic GT1-7 neurons. Endocrinology (1998) 140:5322–3.

86. Movsas TZ, Weiner RL, Greenberg MB, Holtzman DM, Galindo R. Pretreatment with human chorionic gonadotropin protects the neonatal hypothalamic GT1-7 neurons from neuronal damage in vitro. Endocrinology (1999) 140:5322–3.

87. Dendritic spine geometry is critical for AMPA receptor expression in the hippocampus. Trends Neurosci. (1998) 21:545–59.

88. Mak GK, Enwere EK, Gregg C, Pakarainen T, Poutanen M, Hultaniem I, et al. Male pheromone-stimulated neurogenesis in the adult female brain: possible role in mating behavior. Nat Neurosci. (2007) 10:1003–11. doi: 10.1038/nn1828

89. Balari A, Pillemer K, Phillips HS, Kohler M, Rosemblit N, Nikolics K, et al. Lutropin-choriogonadotropin receptor: an unusual member of the G protein-coupled receptor family. Cell (2008) 132:645–60. doi: 10.1016/j.cell.2008.01.033

90. Yu E-J, Nasipaik BT, Kelley DB. Direct action of gonadotropin in brain integrates behavioral and reproductive functions. Proc Natl Acad Sci USA. (2007) 104:2477–82. doi: 10.1073/pnas.0608391104

91. Monen KMJ, Monen B. Structure, function and regulation of gonadotropin receptors - A perspective. Mol Cell Endocrinol. (2012) 356:88–97. doi: 10.1016/j.mce.2012.01.021

92. McFarland KC, Sprengel R, Phillips HS, Kohler M, Rosemblit N, Nikolics K, et al. Lutropin-choriogonadotropin receptor: an unusual member of the G protein-coupled receptor family. Science (1991) 250:494–9. doi: 10.1126/science.1136027

93. Meng XL, Rennert OM, Chan WY. Human chorionic gonadotropin induces neuronal differentiation of PC12 cells through activation of stably expressed lutropin/choriogonadotropin receptor. Endocrinology (1997) 148:5865–7. doi: 10.1210/en.2007-0941

94. Gallego MJ, Poyarette P, Kaltcheva MM, Bowen RL, Vadakkadath Meethal S, Atwood CS. The pregnancy hormones human chorionic gonadotropin and progesterone induce human embryonic stem cell proliferation and differentiation into neuroectodermal rosettes. Stem Cell Res Ther. (2010) 1:28. doi: 10.1186/scrt28

95. Monovas TZ, Stein RL, Greenberg MB, Holtzman DM, Galindo R. Treatment with human chorionic gonadotropin protects the neonatal brain against the effects of hypoxic-ischemic injury. Front Pediatr. (2017) 5:232. doi: 10.3389/fped.2017.00323

96. Emanuele N, Oslapas R, Connick E, Kirsteins L, Lawrence AM. Hypothalamic LH may play a role in control of pituitary LH release. Neuroendocrinology (1981) 33:12–7. doi: 10.1111/j.1752-1688.2007.00005.x

97. David MA, Fraschini F, Martini L. Control of LH secretion: role of a “Short” feedback mechanism. Endocrinology (1966) 78:55–60. doi: 10.1210/endo-78-1-55

98. Hirono M, Igarashi M, Matsumoto S. The direct effect of HCG upon pituitary gonadotrophin secretion. Endocrinology (1972) 90:1214–9. doi: 10.1210/endo-90-5-1214

99. Molitch M, Edmonds M, Jones EE, Odell WD. Short-loop feedback control of luteinizing hormone in the rabbit. Am J Physiol. (1976) 230:907–10.

100. Patritti-laborde N, Wolfsen ADAR, Heber D, Odell WD. Luteinizing hormone in the rabbit. J Clin Invest. (1979) 64:1066–9.

101. Hu Z. Hormonal regulation of LH receptor mRNA and expression in the rat ovary. FEBS Lett. (1990) 274:181–4. doi: 10.1016/0014-5793(90)81359-V

102. Segaloff DL, Sprengel R, Nikolics K, Ascoli M. Structure of the lutropin/choriogonadotropin receptor. Recent Prog Horm Res. (1990) 46:261–3.
112. Min KS, Liu X, Fabritz J, Jaquette J, Abell AN, Ascoli M. Mutations that induce constitutive activation and mutations that impair signal transduction modulate the basal and/or agonist-stimulated internalization of the lutropin/choriogonadotropin receptor. *J Biol Chem.* (1998) 273:34911–9. doi: 10.1074/jbc.273.52.34911

113. Kishi M, Liu X, Hirakawa T, Reczek D, Bretscher A, Ascoli M. Identification of two distinct structural motifs that, when added to the C-terminal tail of the rat LH receptor, redirect the internalized hormone-receptor complex from a degradation to a recycling pathway. *Mol Endocrinol.* (2001) 15:1624–35. doi: 10.1210/me.15.9.1624

114. Burnham V, Sundby C, Laman-Maharg A, Thornton J. Luteinizing hormone acts at the hippocampus to dampen spatial memory. *Horm Behav.* (2017) 89:55–63. doi: 10.1016/j.yhbeh.2016.11.007

115. Lin J, Li X, Yuan F, Lin L, Cook CL, Rao CV, et al. Genetic ablation of luteinizing hormone receptor improves the amyloid pathology in a mouse model of alzheimer disease. *J Neuropathol Exp Neurol.* (2010) 69:253–61. doi: 10.1097/NEN.0b013e3181d072cf

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.